Table 3.

Linear model (GLM) with coefficients showing differences in length of hospitalization during the index hospitalization.

Matched Sibling Donor			Matched Unrelated Donor
Characteristics	Coefficient	P value	Coefficient	P value
G-CSF	0.18	0.78	−1.9	0.02
Gender: Male	0.9	0.10	0.3	0.59
Race: Caucasian	−2.8	0.003	−2.1	0.16
Race: African American	−2.5	0.09	−0.4	0.86
Ethnicity: Hispanic (vs non- Hispanic)	1.8	0.02	3.5	0.008
Performance score <90	1.1	0.05	2.7	<.001
HCT-comorbidity index ≥3	0.5	0.35	0.8	0.23
CMV Positive/Negative	1.3	0.12	−0.2	0.83
CMV Negative/Positive	0.4	0.50	−0.2	0.82
CMV Negative/Negative	0.7	0.35	0.2	0.77
Disease: AML	−0.7	0.29	−0.8	0.33
Disease: ALL	−0.8	0.44	−0.7	0.60
High/very high disease risk index	2.2	0.10	−0.2	0.86
Intermediate disease risk index	2.6	0.04	−0.7	0.65
Time to transplant from diagnosis(< 1 year)	−0.6	0.31	−0.2	0.72
Period of transplant 2007-2011	1.3	0.03	1.4	0.04
TBI containing myeloablative regimen	1.4	0.04	1.9	0.04
TBI containing reduced intensity regimen	−2.0	0.10	−1.9	0.17
Non TBI containing reduced intensity regimen	0	0.97	−1.0	0.22
Calcineurin inhibitor + Mycophenolate	−0.7	0.43	−5.3	<0.001
Calcineurin inhibitor + methotrexate	−1.0	0.19	−4.7	<0.001
Acute GVHD Grade 2-4	4.0	<0.001	4.6	<0.001
Viral infection	0.1	0.82	0.6	0.34
Bacterial infection	1.7	0.002	2.1	0.002
Fungal infection	0	0.98	1.9	0.14

Baseline variables for the model (categorical variables):

Gender: Female; Race: Asian and others; Ethnicity: Non-Hispanic; Performance score: 90-100; HCT-CI:0-2; CMV status: Positive/Positive; Disease: MDS; Time from transplant to diagnosis: > 1 year; Period of transplant: 2012-2016;

Conditioning regimen: Non TBI containing myeloablative regimen; GVHD Prophylaxis: calcineurin inhibitor + others